Schizophrenia Clinical Trial
— SCHIZO'TRAUMAOfficial title:
Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology. SCHIZO' TRAUMA
Verified date | January 2024 |
Source | Centre Hospitalier Universitaire de Saint Etienne |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Childhood trauma is known as a vulnerability factor in schizophrenia. In healthy volunteers, these adversities are linked to a decrease of grey matter of the brain, similar to those observed in schizophrenia. In a previous study based on Voxel-Based Morphometry (VBM), including 21 schizophrenic patients and 30 healthy volunteers, the investigators shown a negative correlation between emotional neglect (important dimension in childhood trauma) and grey matter decrease. This strong correlation was significantly higher in schizophrenic patients than in healthy volunteers, suggesting a higher genetic predisposition to environmental factors in schizophrenic people. Currently, interaction between genetic predisposition and environmental stress factors is the major model for understanding in schizophrenia. In order to analyze both effects on human body, particularly on brain, several studies currently focus on the product of genetic expression, the ribonucleic acid (ARN). The purpose of this study is to provide an explanatory model of links between childhood trauma, candidate gene for schizophrenia expression, cerebral morphology and schizophrenic symptomatology. Using conceptual framework of stress vulnerability, structural equation modeling (SEM) will allow testing causal link between these different variables.
Status | Completed |
Enrollment | 78 |
Est. completion date | November 30, 2023 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria of patients : - For women with reproductively active age period: suitable contraceptive method and negative pregnancy test - Schizophrenia diagnosis (according to DSM 5) - Regular follow-up care at hospital - No change in antipsychotic medication (medication AND dosage) within at least six weeks - Patient into remission : constant dosage, out-patient and meeting Andreassen criteria - Who have given their informed consent before participating in the study. - Physical examination without significant clinical physical anomaly - No serious somatic pathology - Affiliates or entitled to a social security scheme Exclusion Criteria of patients : - For women with reproductively active age period: no suitable contraceptive method (oral, hormonal, intramuscular, intrauterine device, or surgical) - Pregnancy or breastfeeding - Not meeting schizophrenic criteria according to DSM 5 or presenting resistant schizophrenic criteria according Kane criteria - Presenting a serious somatic disorder or neurological (particularly Parkinson disease, epilepsy, tardive dyskinesia) - Cardiovascular, hepatic or serious renal diseases - Contraindication to MRI examination, particularly ocular or intracranial metallic foreign object,pacemaker, artificial heart valve, surgical clip - Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with MRI 3Tesla - Alcohol or drug addiction, within the last year - Recruited in other clinical trial or exclusion period from previous trial. - Susceptibility to self-harm behaviour according to investigator Inclusion Criteria of Related volunteers : - Age, gender and socio-educational level similar to recruited patients - Who have given their informed consent before participating in the study. - First degree relative of schizophrenic patient diagnosed according DSM IV criteria - No schizophrenia diagnosis according DSM IV criteria - No psychiatric history and free of psychotropic drugs/treatment - Physical examination without significant clinical anomaly - Affiliates or entitled to a social security scheme Exclusion Criteria of Related volunteers : - For women with reproductively active age period: no suitable contraceptive method (oral, hormonal, intramuscular, intrauterine device, or surgical) - Pregnancy or breastfeeding - Presenting somatic, neurological or psychiatric disorder - Alcohol or drug addiction, within the last year - Recruited in other clinical trial or exclusion period from previous trial. - Contraindication to MRI examination, particularly ocular or intracranial metallic foreign object, pacemaker, artificial heart valve, surgical clip - Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with MRI 3Tesla Inclusion Criteria of Healthy volunteers : - Age, gender and socio-educational level similar to recruited patients - Who have given their informed consent before participating in the study. - No schizophrenia diagnosis according DSM IV criteria - No personal or family history of psychiatric disorders - Free of psychotropic drugs/treatment - Physical examination without significant clinical anomaly - Affiliates or entitled to a social security scheme Exclusion Criteria of Healthy volunteers : Beside the absence of schizophrenia diagnosis, healthy volunteers should meet the same exclusion criteria as patients |
Country | Name | City | State |
---|---|---|---|
France | CHU de Saint Etienne | Saint-Étienne |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Saint Etienne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Childhood Trauma Questionnaire (CTQ) for childhood trauma. | development of an etiopathogenic model characteristic of schizophrenia Childhood Trauma Questionnaire : to assess five types of childhood trauma : Emotional neglect physical abuse emotional abuse physical neglect sexual abuse Each item being rated in 5 answer choice from 1 to 5 (never, rarely, sometimes, often or very often) |
5 days | |
Primary | Quantitative measurement of RNAs | development of an etiopathogenic model characteristic of schizophrenia | 5 days | |
Primary | Voxel-based morphometry (VBM) for total gray matter | development of an etiopathogenic model characteristic of schizophrenia | 5 days | |
Primary | Voxel-based morphometry (VBM) for regional gray matter density. | development of an etiopathogenic model characteristic of schizophrenia | 5 days | |
Secondary | Connectivity in the cortico-limbic circuit | 5 days | ||
Secondary | Volumetry of the brain | 5 days | ||
Secondary | Correlation of BOLD activity in the cortico-limbic circuit in patients with patients with symptomatic variables | symptomatic variables : PANSS scale | 5 days | |
Secondary | Correlation of BOLD activity in the cortico-limbic circuit with emotional variables | emotional variables : ERS scale, ERQ scale, TAS-20 scale, SAS scale, AES-C scale | 5 days | |
Secondary | Correlation of BOLD activity in the cortico-limbic circuit with personality characteristics | personality characteristics : EPQ-R scale, SPQ scale | 5 days | |
Secondary | Correlation of BOLD activity in the cortico-limbic circuit with history of trauma in childhood | history of trauma in childhood : CTQ scale | 5 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |